Condylomata Acuminata Clinical Trial
Official title:
A PhaseⅡ Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years
Verified date | June 2023 |
Source | Xiamen University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase Ⅱ clinical study was designed to evaluate the immunogenicity and safety of the novel recombinant HPV type 6/11 bivalent vaccine, manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged 18-55 years of age at enrollment. The study volunteers would be randomized to receive the 3 different formulations of the novel HPV vaccine or placebo vaccine (recombinant hepatitis E vaccine) administered intramuscularly according to a 0-1-6 month schedule. This is a double-blind study.
Status | Active, not recruiting |
Enrollment | 640 |
Est. completion date | December 30, 2023 |
Est. primary completion date | December 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Participants aged between 18 and 55 years. 2. Judged as healthy and eligible for vaccination by the investigators through a self-reported medical history and some physical examinations. 3. Written informed consent obtained from the participants. 4. Able to comply with the requests of the study. 5. Axillary temperature not higher than 37.0°C 6. Non-pregnancy verified by a urine pregnancy test. Exclusion Criteria: 1. Pregnant or breastfeeding or plan to be pregnant within 7 months. 2. Use of any investigational product or non-registered product (drug or vaccine) within 30 days preceding the first dose of the study vaccine or plan to use during the study period. 3. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment. 4. Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine. 5. Administration of any attenuated live vaccines within 30 days preceding the first dose of the study vaccine or any subunit or inactivated vaccines within 14 days before vaccination. 6. Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring systemic antibiotics or antiviral treatment within 5 days before vaccination. 7. Having the plan to participate another clinical trial during the study period. 8. Received another HPV vaccine. 9. Immunodeficiency (such as HIV carriers), primary disease of important organs, malignant tumor, .or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response). 10. History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy, urticaria, dyspnea, angioneurotic edema or abdominal pain. 11. Having serious disease of internal medicine, such as hypertension, cardiac disease, diabetes, hyperthyroidism et al. 12. Asthma that required emergent treatment, hospitalization, oral or intravenous corticosteroid for unstable condition within the past 2 years. 13. Diagnosed coagulant function abnormality (i.e., clotting factors absent, clotting hemorrhagic disease, abnormal platelet function) or blood coagulation disorder. 14. Epilepsy, except fever epilepsy at under 2 years of age, alcohol-induced epilepsy in 3 years before abstinence, or idiopathic epilepsy requiring no treatment in the past 3 years. 15. Past or current two-stage affective psychosis, not well controlled in the past 2 years or requiring drugs, or h a tendency to commit suicide. 16. Other medical, psychological, social or occupational factors that, according to the investigators' judgment, might affect the individual's ability to obey the protocol or sign the informed consent. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Jun Zhang | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen Innovax Biotech Co., Ltd |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Anti-HPV 6 and anti-HPV 11 seroconversion rates (type specific IgG antibody) | 7 months | ||
Primary | Anti-HPV 6 and anti-HPV 11 geometric mean concentrations (type specific IgG antibody) | 7 months | ||
Secondary | Number of serious adverse events throughout the study | All the serious adverse events throughout the study would be recorded. | 7 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Completed |
NCT00090285 -
An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)
|
Phase 3 | |
Completed |
NCT00973856 -
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
|
N/A | |
Completed |
NCT02015260 -
A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts
|
Phase 2 | |
Active, not recruiting |
NCT05056402 -
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
|
Phase 3 | |
Withdrawn |
NCT00365443 -
Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)
|
Phase 2 | |
Not yet recruiting |
NCT01483794 -
Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile
|
N/A | |
Completed |
NCT03935204 -
Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 2 | |
Completed |
NCT02405520 -
Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
|
Phase 1 | |
Completed |
NCT04782895 -
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
|
Phase 3 | |
Completed |
NCT03546842 -
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
|
Phase 3 | |
Completed |
NCT03981822 -
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
|
Phase 2 | |
Recruiting |
NCT03158480 -
Safety and Efficacy of Immune Therapy for Condyloma
|
N/A | |
Completed |
NCT01598779 -
Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
|
N/A | |
Not yet recruiting |
NCT06430190 -
Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata
|
N/A | |
Completed |
NCT00449982 -
Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts
|
Phase 3 | |
Completed |
NCT03813940 -
Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 1 | |
Not yet recruiting |
NCT06197802 -
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
|
||
Completed |
NCT01532102 -
Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06297187 -
Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study
|